{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T03:07:09Z","timestamp":1767841629893,"version":"3.49.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Sofosbuvir is not recommended in persons with estimated glomerular filtration rate (eGFR) &amp;lt;30\u2009mL\/min. We report the results of treatment with an off-label 8-week regimen of daclatasvir and half-dose sofosbuvir in patients with acute infection with\u00a0hepatitis C virus ( HCV) and eGFR &amp;lt;30\u2009mL\/min.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Clinic records were searched to identify treatment-na\u00efve, noncirrhotic adults with acute hepatitis C (HCV viremia and a \u226510-fold elevation of serum alanine aminotransferase activity) and eGFR &amp;lt;30\u2009mL\/min, who had been treated with a sofosbuvir-based regimen. Treatment response was assessed using serum HCV RNA testing at 4\u2009weeks of treatment, end of the 8-week treatment and 12\u2009weeks after stopping treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 31 patients with acute hepatitis C, 27 [median age (range): 36 (18\u201374) years; 20 (74%) male] were started on treatment with 200\u2009mg sofosbuvir and 60\u2009mg daclatasvir daily for 8\u2009weeks, irrespective of HCV genotype. All the 27 completed the planned 8-week treatment. One patient died 10\u2009weeks after completing the treatment of an unrelated cause. All the 27 patients had undetectable HCV RNA after 4\u2009weeks of and at the end of treatment. At 12\u2009weeks after completion of treatment, only one tested HCV RNA positive and 25 were negative, with sustained virological response rate of 25\/27 (92.6%) and 25\/26 (96.2%) on intention-to-treat and per-protocol basis, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Eight-week course of daclatasvir and half-dose sofosbuvir is effective for acute hepatitis C in patients with eGFR\u2009&amp;lt;30\u2009mL\/min and could be a useful alternative to costly, kidney-safe anti-HCV oral drugs in resource-constrained settings.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfaa187","type":"journal-article","created":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T11:19:10Z","timestamp":1592651950000},"page":"1867-1871","source":"Crossref","is-referenced-by-count":12,"title":["Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir"],"prefix":"10.1093","volume":"36","author":[{"given":"Amit","family":"Goel","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dharmendra S","family":"Bhadauria","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anupma","family":"Kaul","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhai","family":"Verma","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prachi","family":"Tiwari","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumit","family":"Rungta","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, King George\u2019s Medical University, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praveer","family":"Rai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"key":"2021092718221832700_gfaa187-B1","doi-asserted-by":"crossref","first-page":"e2113","DOI":"10.1097\/MD.0000000000002113","article-title":"Interferon-based treatment of hepatitis C virus infection reduces all-cause mortality in patients with end-stage renal disease: an 8-year nationwide cohort study in Taiwan","volume":"94","author":"Hsu","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"2021092718221832700_gfaa187-B2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s12664-018-0920-3","article-title":"Hepatitis C virus infection and chronic renal disease: a review","volume":"37","author":"Goel","year":"2018","journal-title":"Indian J Gastroenterol"},{"key":"2021092718221832700_gfaa187-B3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/jgh.14466","article-title":"Burden of hepatitis C virus infection in India: a systematic review and meta-analysis","volume":"34","author":"Goel","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"2021092718221832700_gfaa187-B4","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1093\/cid\/cit296","article-title":"Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy","volume":"57","author":"Martin","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2021092718221832700_gfaa187-B5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1473-3099(16)30408-X","article-title":"Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study","volume":"17","author":"Deterding","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2021092718221832700_gfaa187-B6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL Recommendations on Treatment of Hepatitis C 2018","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"2021092718221832700_gfaa187-B7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.kisu.2018.06.001","article-title":"KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease","volume":"8","year":"2018","journal-title":"Kidney Int Suppl (2011)"},{"key":"2021092718221832700_gfaa187-B8","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/nep.12833","article-title":"Safety and effectiveness of response-guided therapy using pegylated interferon and ribavirin for chronic hepatitis C virus infection in patients on maintenance dialysis","volume":"22","author":"Goel","year":"2017","journal-title":"Nephrology (Carlton"},{"key":"2021092718221832700_gfaa187-B9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/nep.13222","article-title":"Daclatasvir and reduced-dose sofosbuvir: an effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate &lt;30 mL\/min","volume":"24","author":"Goel","year":"2019","journal-title":"Nephrology (Carlton)"},{"key":"2021092718221832700_gfaa187-B10","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2021092718221832700_gfaa187-B11","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2012.07.007","article-title":"Case definitions for acute hepatitis C virus infection: a systematic review","volume":"57","author":"Hajarizadeh","year":"2012","journal-title":"J Hepatol"},{"key":"2021092718221832700_gfaa187-B12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/0003-4819-117-3-215","article-title":"The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites","volume":"117","author":"Runyon","year":"1992","journal-title":"Ann Intern Med"},{"key":"2021092718221832700_gfaa187-B13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jhep.2015.06.004","article-title":"Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease","volume":"63","author":"Bhamidimarri","year":"2015","journal-title":"J Hepatol"},{"key":"2021092718221832700_gfaa187-B14","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/apt.14429","article-title":"Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis","volume":"47","author":"He","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2021092718221832700_gfaa187-B15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/hep.29611","article-title":"Should we treat acute hepatitis C? A decision and cost-effectiveness analysis","volume":"67","author":"Bethea","year":"2018","journal-title":"Hepatology"},{"key":"2021092718221832700_gfaa187-B16","first-page":"667A","article-title":"Anti-viral efficacy and pharmacokinetics (PK) of sofosbuvir (SOF) in patients with severe renal impairment","volume":"60","author":"Gane","year":"2014","journal-title":"Hepatology"},{"key":"2021092718221832700_gfaa187-B17","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/ndt\/gfn684","article-title":"Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data","volume":"24","author":"Johnson","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"2021092718221832700_gfaa187-B18","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S2468-1253(18)30414-X","article-title":"Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial","volume":"4","author":"Boerekamps","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2021092718221832700_gfaa187-B19","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/cid\/ciy913","article-title":"Ledipasvir\/sofosbuvir for 8 weeks to treat acute hepatitis C virus infections in men with human immunodeficiency virus infections: sofosbuvir-containing regimens without interferon for treatment of acute HCV in HIV-1 infected individuals","volume":"69","author":"Naggie","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021092718221832700_gfaa187-B20","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2019.05.028","article-title":"Sofosbuvir\/velpatasvir for 12weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis","volume":"71","author":"Borgia","year":"2019","journal-title":"J Hepatol"},{"key":"2021092718221832700_gfaa187-B21","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N Engl J Med"},{"key":"2021092718221832700_gfaa187-B22","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/36\/10\/1867\/40448811\/gfaa187.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/36\/10\/1867\/40448811\/gfaa187.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T21:07:56Z","timestamp":1632776876000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/36\/10\/1867\/5937262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":22,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10,23]]},"published-print":{"date-parts":[[2021,9,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaa187","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2020,10,23]]}}}